These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7784282)

  • 21. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Once daily, low dose, short term antithyroid drug treatment of Graves' disease is followed by an unacceptably high relapse rate.
    Ford HC; Feek CM; Delahunt JW
    N Z Med J; 1991 Mar; 104(907):97-8. PubMed ID: 2006072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid stimulating immunoglobulin bioactivity during carbimazole therapy as measured by the cytochemical bioassay.
    Prentice MG; Rayman GA; Alaghband-Zadeh J; Wise PH
    J Endocrinol Invest; 1987 Oct; 10(5):483-9. PubMed ID: 2892877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma free triiodothyronine response to thyrotropin-releasing hormone to predict the remission of Graves' disease treated with antithyroid drugs.
    Notsu K; Oka N; Masaki Y; Furuya H; Kato Y
    J Clin Endocrinol Metab; 1991 Aug; 73(2):396-400. PubMed ID: 1713218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs.
    Jonas M; Ambroziak U; Bednarczuk T; Nauman J
    Endokrynol Pol; 2006; 57(6):596-604. PubMed ID: 17253432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L; Chin L; Daykin J; Allahabadia A; Heward J; Gough SC; Savage CO; Franklyn JA
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
    Kung AW; Lau KS; Kohn LD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remission with carbimazole therapy & assessment of T4 suppression test as an index of relapse in patients with Graves' disease in India.
    Goswami R; Bal CS; Gupta N; Kochupillai N
    Indian J Med Res; 1996 May; 103():272-7. PubMed ID: 8707364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R; Quadbeck B; Roggenbuck U; Szabolcs I; Pfeilschifter J; Meng W; Reschke K; Hackenberg K; Dettmann J; Prehn B; Hirche H; Mann K;
    Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum TSH level as predictor of Graves' disease recurrence following antithyroid drug withdrawal: A systematic review.
    Subekti I; Kartiko GJ; Suhardi ZF; Muhadi ; Wisnu W
    PLoS One; 2021; 16(1):e0245978. PubMed ID: 33513181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
    Buerklin EM; Schimmel M; Utiger RD
    J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.